Peter Marks looks up while testifying at a hearing -- coverage from STAT
Peter Marks was forced out as the director of the FDA’s Center for Biologics Evaluation and Research.SUSAN WALSH/POOL/AFP via Getty Images

Matthew Herper covers medical innovation — both its promise and its perils.

The forced resignation of Peter Marks, the Food and Drug Administration official in charge of regulating vaccines, gene therapies, and the blood supply, led to panic over the weekend in the worlds of public health and biopharmaceuticals — two worlds that often agree on very little aside from their belief in the safety and effectiveness of vaccines.

There were also some dissenters: those who argued one person is simply not important enough to raise concerns this big. Besides, they said, Marks made mistakes that were significant enough to justify firing him. 

Advertisement

That counterargument is wrong. Even if Marks were inconsequential or incompetent, his removal matters a great deal.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $399/year

$30 for 3 months Get Started

Then $399/year

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe